A cellular device to target cancer cells

buir.advisorŞeker, Urartu Özgür Şafak
dc.contributor.authorOstaku, Julian
dc.date.accessioned2021-10-08T13:39:55Z
dc.date.available2021-10-08T13:39:55Z
dc.date.copyright2021-10
dc.date.issued2021-10
dc.date.submitted2021-10-07
dc.departmentGraduate Program in Materials Science and Nanotechnologyen_US
dc.descriptionCataloged from PDF version of article.en_US
dc.descriptionThesis (Master's): Bilkent University, Department of Materials Science and Nanotechnology, İhsan Doğramacı Bilkent University, 2021.en_US
dc.descriptionIncludes bibliographical references (pages 64-68).en_US
dc.description.abstractCancer is the second leading cause of death globally, affecting one out of three people during their lifetime. Due to its severity and high incidence, numerous treatment methods have been implemented, with the Chimeric Antigen Receptor T-Cell (CAR-T) therapy remaining the most promising one. Other therapy options such as surgery, chemotherapy and radiation therapy remain the backbone of cancer treatment, however these therapies are not effective enough as they do not discriminate among the healthy and cancerous tissues. Therefore, there is an imperative need in developing novel cancer treatment therapies that offer precise localization and on target therapeutics release. In this study, we aim to develop an engineered bacterial device, that can sense Jimt1 breast cancer cells, which are characterized by overexpression of human epidermal growth factor receptor 2 (HER2). 2Rs15d, a nanobody that binds to HER2 receptor, is expressed on the surface of Escherichia coli BL21 (DE3) via Ag43 autotransporter protein. Upon localization in the tumor site, a therapeutic agent will be released on the outer surface. By creating this platform, we aim to target the main problems of the existing cancer therapies.en_US
dc.description.degreeM.S.en_US
dc.description.provenanceSubmitted by Betül Özen (ozen@bilkent.edu.tr) on 2021-10-08T13:39:55Z No. of bitstreams: 1 10425489.pdf: 5145934 bytes, checksum: 41d118b6438334240d13ea6a4aa41ec0 (MD5)en
dc.description.provenanceMade available in DSpace on 2021-10-08T13:39:55Z (GMT). No. of bitstreams: 1 10425489.pdf: 5145934 bytes, checksum: 41d118b6438334240d13ea6a4aa41ec0 (MD5) Previous issue date: 2021-10en
dc.description.statementofresponsibilityby Julian Ostakuen_US
dc.embargo.release2022-04-06
dc.format.extentxxiii, 92 leaves : illustrations ; 30 cm.en_US
dc.identifier.itemidB132845
dc.identifier.urihttp://hdl.handle.net/11693/76607
dc.language.isoEnglishen_US
dc.publisherBilkent Universityen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLiving therapeuticsen_US
dc.subjectBreast cancer cellsen_US
dc.subjectHER2en_US
dc.subjectSecretionen_US
dc.subjectNanobodyen_US
dc.titleA cellular device to target cancer cellsen_US
dc.title.alternativeTümörleri hedeflemek için hücresel bir cihazen_US
dc.typeThesisen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
10425489.pdf
Size:
4.91 MB
Format:
Adobe Portable Document Format
Description:
Full printable version
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.69 KB
Format:
Item-specific license agreed upon to submission
Description: